ArticleJournal of the National Cancer Center2023
Quality of life and survival outcomes of patients with inoperable esophageal squamous cell carcinoma after definitive radiation therapy: A multicenter retrospective observational study in China from 2015 to 2016.
Article in Journal of the National Cancer Center, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Nimotuzumab Combined With Concurrent Curative Radiotherapy and S-1 in 75 Years and Older Patients With Stage II-IVB Esophageal Squamous Cell Carcinoma: A Phase II Study.International journal of cancer · 2026Trial
- Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.BMC medicine · 2025Trial
- Upfront or deferred radiotherapy combined with chemoimmunotherapy for inoperable oesophageal squamous cell carcinoma: a target trial emulation in China.EClinicalMedicine · 2026Article
- Review
- Single-Cell RNA Sequencing Identifies a Distinct Epithelial Subpopulation Driving Resistance to Neoadjuvant Chemoimmunotherapy in Esophageal Squamous Cell Carcinoma.Biological procedures online · 2026Article
- The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.Frontiers in oncology · 2026Article
- Longitudinal CT-based deep learning radiomics for predicting prognosis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a two-center study.Journal of Cancer · 2026Article
- Association of Naples Prognostic Score with Survival in Patients with Inoperable Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy Combined with Immunotherapy.Journal of inflammation research · 2026Article
- Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study.Cancer biology & therapy · 2025Article
- Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients.Future science OA · 2025Article
- Discovery and validation of proliferative exhausted T cells as a favorable prognostic biomarker in esophageal squamous cell carcinoma.Scientific reports · 2025Article
- Optimal Hospital Volume to Minimize Postoperative Mortality After Esophagectomy for Cancer in Low Population Density Countries: A Binational Study of Australia and New Zealand.World journal of surgery · 2025Article
- Multi-modal radiomics features to predict overall survival of locally advanced esophageal cancer after definitive chemoradiotherapy.BMC cancer · 2025Article
- A nomogram for predicting cancer-specific survival in patients with locally advanced unresectable esophageal cancer: development and validation study.Frontiers in immunology · 2025Article
- Prognostic impact of CT-derived muscle-adipose index change in patients with inoperable esophageal squamous cell carcinoma undergoing chemoradiotherapy.Frontiers in oncology · 2025Article
- Preliminary exploration of radiotherapy timing following induction chemoimmunotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-center retrospective study.Frontiers in oncology · 2025Article
- S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.Cancer biology & therapy · 2024Article
- Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Exosomes in esophageal cancer: a promising frontier for liquid biopsy in diagnosis and therapeutic monitoring.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the health-related quality of life (HRQL) of long-term survivors of inoperable esophageal squamous cell carcinoma (ESCC) treated with definitive radiation therapy, the real-world trends in the use of advanced radiation techniques, and their impact on the survival outcomes of ESCC patients. Methods: In this multicenter retrospective observational study, the medical records related to demographics and treatment of ESCC patients who were treated with definitive radiation therapy at 14 provincial hospitals in China from 1 January 2015 to 31 December 2016 were analyzed. A HRQL questionnaire was completed by survivors and collected by doctors at the final follow-up. The difference in quality of life between patients with or without recurrence was compared using the Wilcoxon-Mann-Whitney test. Overall survival (OS) was estimated using the Kaplan-Meier method and the group differences were assessed by unstratified log-rank test. The Cox proportional hazards model with Efron's method of tie handling was used to calculate the risk factors for OS. Results: The data of a total of 3,308 patients were collected for this study, 248 were excluded because of missing data, and a final of 3,060 patients were included in the analysis. Most patients (2,901; 94.8%) received intensity-modulated radiotherapy (IMRT)/volumetric-modulated arc therapy (VMAT)/tomotherapy (TOMO). The 5-year OS rate was 30%. Patients who received either two-dimensional radiotherapy (2DRT; HR, 2.43 [95% CI, 1.70-3.47]; Conclusions: This large, multicenter retrospective study on ESCC patients who received definitive radiation therapy found that most ESCC survivors are satisfied with their quality of life. Most patients received advanced radiation technology. Patients who received either 2DRT or 3DRT had a significantly increased risk of death compared to those who received advanced radiation technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.